Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with relapsed
or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Sunitinib may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the cancer.